Treace Medical Lifts 2026 Revenue Outlook to $204M-$212M
TMCI has more than doubled off its 52-week low of $1.17.
Summary
Treace Medical raised its 2026 revenue guidance to $204M-$212M, up from the prior $202M-$212M range, with the midpoint moving to $208M. The company now expects a 2026 adjusted EBITDA loss of $3M to $5M, improved from the previous guidance of a loss of $4M to $6M. This follows the Q2 2026 report showing a 4% revenue decline but narrowing losses. The guidance lift suggests management sees improving trends in the second half. With a market cap around $284M, even small revenue beats can move the stock. The company has been cutting costs, and CEO John Treace has been buying shares in recent months, adding to the positive signal.
At the time of this announcement, TMCI was trading at $4.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $284.1M. The 52-week trading range was $1.17 to $7.78. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.